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Purpose: To apply recently developed predictive models for swallowing dysfunction to 
compare the predicted probabilities of swallowing dysfunction for standard intensity 
modulated radiotherapy (ST-IMRT) and swallowing sparing IMRT (SW-IMRT). 
Material and Methods: Thirty head and neck cancer patients who previously underwent 
radiotherapy for the bilateral neck were selected for this study. For each patient, ST-IMRT 
and SW-IMRT simultaneous integrated boost treatment plans were created. ST-IMRT 
treatment plan optimization aimed at obtaining adequate target volume coverage and 
sparing of the parotid and submandibular glands as much as possible. Objectives for SW-
IMRT were similar, with additional objectives to spare the organs at risk related to swal-
lowing dysfunction (SWOARs). Dose-volume data with ST-IMRT and SW-IMRT and normal 
tissue complication probabilities for physician-rated and patient-rated swallowing dys-
function were calculated with recently developed predictive models. 
Results: All plans had adequate target volume coverage and dose to critical organs was 
within accepted limits. Sparing of parotid glands was similar for ST-IMRT and SW-IMRT. 
With SW-IMRT, the mean dose to the various SWOARs was reduced. Absolute dose values 
and dose reductions with SW-IMRT differed per patient and per SWOAR and depended 
on N stage and tumor location. The mean reduction in predicted physician-rated Radiation 
Therapy Oncology Group (RTOG) grade 2-4 swallowing dysfunction was 9% (range, 3-
20%). Mean reductions of the probability of patient-rated moderate to severe complaints 
with regard to the swallowing of solid food, soft food, liquid food and chocking when swal-
lowing were 8%, 2%, 1% and 1%, respectively. 
Conclusions: New predictive models for swallowing dysfunction were applied to show po-
tential reductions in physician and patient-rated swallowing dysfunction with IMRT that 
was specifically optimized to spare SWOARs. 
  




Target volumes in HNC patients are generally large, have complex concave shapes and are 
surrounded by numerous sensitive and critical organs at risk (OARs). This has challenged 
radiation oncologists for decades in their attempts to avoid and reduce radiation-induced 
side effects that typically strike HNC patients. The clinical introduction of intensity modu-
lated radiotherapy (IMRT) in the treatment of head and neck cancer (HNC) significantly 
improved outcome in terms of prevention of hyposalivation and reduction of radiation-
induced xerostomia compared to three-dimensional conformal radiotherapy (3D-CRT)1–4. 
Although the implementation of intensified fractionation schedules and the use of con-
comitant chemotherapy has led to a significant improvement of locoregional tumor con-
trol and overall survival2,5–8, the risk of invalidating side effects, such as mucositis and per-
sistent swallowing dysfunction and their subsequent impact on quality of life, have in-
creased as well. This highlights the importance of improving existing radiotherapy tech-
niques to reduce the dose in relevant structures as much as possible. With the use of new 
computer assisted optimization methods, such as direct aperture optimization, robust 
IMRT treatment plans with highly conformal dose distributions can be obtained. 
 Since modern IMRT techniques proved to reduce the severity of xerostomia and to 
improve quality of life in HNC patients4, attention has recently been focused to yet an-
other, potentially even more discomforting and invalidating side effect of head and neck 
radiotherapy, i.e., swallowing dysfunction9. Studies have confirmed that various domains 
of swallowing significantly affect how patients rate their quality of life9–13. 
 Recently, we reported on the results of a large multicenter prospective cohort study 
in which we identified the most important dose-volume parameters that determine late 
physician-rated and patient-rated swallowing dysfunction14. In addition, we built multivar-
iable Normal Tissue Complication Probability (NTCP) models taking into account the most 
relevant dose-volume parameters as well as other independent prognostic factors. These 
models can estimate NTCP values in individual patients for different endpoints related to 
swallowing, and, therefore, can also estimate the potential benefit of new radiation tech-
niques aiming at reduction of swallowing dysfunction resulting from radiation. 
 The purpose of the current in silico planning comparative study was to assess the po-
tential benefit of swallowing sparing IMRT (SW-IMRT) reference to standard IMRT (ST-
IMRT), by reducing the dose to relevant anatomical structures involved in swallowing dys-
function. The second aim was to analyze if these dose reductions would translate into 
relevant reduced estimated NTCP values for physician-rated and patient-rated measures 
for swallowing dysfunction using the NTCP models as published in our previous report. 
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Methods and Materials 
Patients and computed tomography 
The population of this study was composed of 30 patients who had previously undergone 
primary radiotherapy for HNC and required elective or therapeutic treatment of both 
sides of the neck (Table 1). The patients were randomly selected from our previous co-
hort14. Contrast enhanced planning computed tomography (CT) scans were acquired in 
treatment position with a slice thickness and index of 2 mm. Radiotherapy treatment plan-
ning was performed in a research version of the Pinnacle3 treatment-planning system (ver-
sion 9.1, Philips Radiation Oncology Systems, Fitchburg, WI, USA). The adaptive convolve 
algorithm was used for all dose calculations. 
 
Table 1: Baseline Patient and Tumor Characteristics 
Characteristic Patients  p-value 
 Current study Model cohort  
 No. % No. %   
 Age, years     0.56 
   18-65  21 70 222 63   
   >65    9 30 132 37   
Tumor location     < .01 
   Larynx    6 20 164 46   
   Hypopharynx    4 13   18 5   
   Oropharynx  16 54   91 26   
   Nasopharynx    4 13   14 4   
   Other    0 0   67 19   
T stage     < .01 
   T0    0 0   16 4   
   T1    3 10   94 18   
   T2  10 33 151 43   
   T3    8 27   68 19   
   T4    9 30   55 16   
N stage     < .01 
   N0    7 23 200 56  
   N1    3 10   39 11   
   N2a    3 10   15 4   
   N2b    5 17   38 11   
   N2c  12 40   53 15   
   N3    0 0     9 3   
P-values represent the result of 2-tailed Pearsons Chi squared test 
Regions of interest 
The definition of the planning target volumes (PTV) that were used in the present study 
was described previously in more detail15–17. All PTVs were restricted to 5 mm within the 
skin surface for the purpose of dose optimization and evaluation. For each patient, two 
PTVs were defined: an elective PTV to which a total dose of 54.25 Gy was prescribed 
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(PTV54), and a high risk PTV for which the prescribed total dose was 70 Gy (PTV70). The 
mean volumes of PTV54 and PTV70 were 709 cm3 and 229 cm3, respectively. The different 
dose levels were prescribed to the PTVs according to a simultaneous integrated boost 
(SIB) technique of 35 fractions, with a daily dose of 1.55 Gy prescribed to PTV54 and a 
daily dose of 2.00 Gy prescribed to PTV70. 
 The following OARs were delineated: the parotid and submandibular salivary glands, 
spinal cord, brainstem, optic nerves and optical chiasm. Structures that we previously 
found to be related to swallowing dysfunction14 including the superior and middle phar-
yngeal constrictor muscle (PCM), as well as the supraglottic larynx and the esophageal 
inlet muscle (EIM), were outlined as swallowing OARs (SWOARs). To ensure consistent 
delineation, all OARs and SWOARs were delineated by a single radiation oncologist ac-
cording to a CT-based delineation protocol for OAR definition in the head and neck region 
developed at our department18,19. 
IMRT treatment planning 
For each patient, two direct aperture optimization (DAO)-based IMRT treatment plans 
were created: a ST-IMRT plan, and a second IMRT plan that was based on the ST-IMRT 
treatment plan, but with additional optimization to reduce the radiation dose to the 
SWOARs (SW-IMRT). Gantry angles and DAO-settings were similar for all plans and all pa-
tients. All plans consisted of seven coplanar 6-MV photon beams (gantry angles: 0°, 50°, 
100°, 150°, 210°, 260°, 310°, collimator rotation: 5°), and DAO settings comprised of a 
minimal segment size of 4 cm2, at least 2 monitor units per segment, and a maximum total 
of 84 step-and-shoot segments for each plan. Each optimization sequence consisted of 30 
automated iterations. Two additional ring shaped structures, each with a width of 4 mm 
were created just inside PTV54 and PTV70 for the purpose of optimizing PTV coverage. 
Optimising ST-IMRT and SW-IMRT 
The primary objectives for ST-IMRT and SW-IMRT were similar: at least 98% of each PTV 
had to be covered with 95% of the prescribed dose, the maximum doses delivered to the 
spinal cord, brainstem, optic nerves and optic chiasm were not allowed to exceed 54 Gy, 
60 Gy, 54 Gy and 54 Gy, respectively. The maximum plan dose was not allowed to exceed 
77 Gy and the volume receiving 75 Gy was not allowed to be larger than 2 cm3. In both 
ST-IMRT and SW-IMRT, it was attempted to reduce the dose to the parotid and subman-
dibular glands and other unspecified tissues outside PTV54 as much as possible. 
 A ST-IMRT plan was created first, based on the aforementioned objectives. By a trial-
and-error adaptive adjustment of the objectives values and weights, the dose plan was 
optimized such that a clinically acceptable plan was obtained. On average, seven optimi-
zation sequences were required before an acceptable ST-IMRT plan was obtained that 
concurred with the plan objectives. 
 Subsequently, the ST-IMRT plan was copied into a SW-IMRT plan. In order to minimize 
the SWOARs doses in the SW-IMRT plan, objective values and weights were added for the 
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SWOARs. On average, 10 additional optimization sequences were required to obtain a SW-
IMRT plan that concurred with the primary plan objectives and also had a minimized dose 
in the SWOARs. The doses to the SWOARs were reduced according to the following order 
of priority: 1) minimizing the superior PCM mean dose, 2) minimizing the mean dose to 
the supraglottic larynx, 3) minimizing the middle PCM mean dose, and 4) minimizing the 
proportion of the EIM receiving ≥60 Gy (EIM V60). This order of priority was based on the 
outcome of the multivariate logistic regression analysis regarding different aspects of 
swallowing dysfunction14. The mean dose in the parotid glands was not allowed to be 
higher with SW-IMRT than with ST-IMRT. 
Dose-volume data and complication probabilities 
Target coverage was determined for all plans by evaluating the relative volume of the PTV 
that received ≥95% of the prescribed dose. Integral volumes receiving ≥51.3 Gy (≥95%*54 
Gy), ≥57.8 Gy (≥107%*54 Gy) and ≥66.5 Gy (≥95%*70 Gy) were determined and relevant 
OAR and SWOAR dose-volume parameters were obtained from corresponding dose-vol-
ume histograms (DVH). 
 In our previous paper we published details on the development of predictive mod-
els14. In brief, for all endpoints related to swallowing dysfunction a multivariate logistic 
regression analysis was used with an extended bootstrapping technique and forward var-
iable selection as described by El Naqa et al.20. The procedure revealed that the most pre-
dictive model for physician-rated Radiation Therapy Oncology Group (RTOG) grade 2-4 
swallowing dysfunction21 was based on the mean dose to the superior PCM and mean 
dose to the supraglottic larynx. For the patient-rated problems we established separate 
predictive models. For problems with solid food, the predictive model consisting of 3 var-
iables was most optimal, including: the mean dose to the superior PCM, the mean dose 
to the supraglottic larynx and age (18-65 versus >65 years). For problems with soft food, 
a 4-factor predictive model was found to be most optimal, including the mean dose to the 
middle PCM, age, tumor site (naso/oropharynx versus other sites) and radiation technique 
(3D-CRT versus IMRT). The model for problems with liquid food consisted of two variables, 
including the mean dose to the supraglottic larynx and radiation technique. Finally, we 
established a model for choking when swallowing, which depended on the EIM V60 and 
the mean dose to the supraglottic larynx. The established NTCP model parameters were 
used to calculate the NTCP values for ST-IMRT and SW-IMRT with regard to physician-
rated RTOG grade 2-4 swallowing dysfunction. In addition, the NTCP values for ST-IMRT 
and SW-IMRT of moderately to severely patient-rated problems as assessed with the 
EORTC QLQ-H&N35 questionnaire22, with respect to the swallowing of solid food, soft 
food, liquid food and chocking when swallowing were calculated. 




PTV coverage and irradiated volumes 
At least 98% of the PTVs received 95% of the prescribed dose in all plans and all patients. 
The absolute integral volumes receiving ≥95% and ≥107% of the dose prescribed to PTV54 
and integral volumes receiving ≥95% of the dose prescribed to PTV70 were generally 
larger with SW-IMRT (Table 2). 
 
Table 2:  Dose-volume data and normal tissue complication probabilities 
 ST-IMRT SW-IMRT 
PTV volumes (cm3)   
   PTV54 709 (452 - 1091)   
   PTV70 229 (36 - 637)   
PTV coverage (%)   
   PTV54, 95% dose/ 98% volume 100% 100% 
   PTV70, 95% dose/ 98% volume 100% 100% 
Integral irradiated volumes (cm3)   
   V51.3 Gy (95%*54.0 Gy) 1236 (586-1882) 1277 (666-1993) 
   V57.8 Gy (107%*54.0 Gy) 496 (97-1153) 528 (110-1178) 
   V66.5 Gy (95%*70 Gy) 300 (51-806) 308 (50-814) 
Max dose (Gy)   
   Integral 74.5 (72.5-75.6) 75.2 (73.2-76.2) 
   Spinal cord 48.6 (43.7-49.9) 48.8 (46.8-50.8) 
Salivary glands mean dose (Gy)   
   Parotid ipsilateral 43.2 (14.6-63.3) 43.3 (14.7-64.9) 
   Parotid contralateral 36.0 (19.0-60.1) 35.7 (19.2-59.8) 
   Submandibular ipsilateral 65.1 (51.3-71.1) 65.7 (51.9-72.1) 
   Submandibular contralateral 61.5 (48.0-70.4) 62.0 (49.2-71.4) 
SWOAR mean dose (Gy)   
   Superior PCM 61.0 (25.8-71.5) 56.3 (9.1-70.9) 
   Middle PCM 61.9 (49.2-71.6) 57.7 (31.2-70.9) 
   Supraglottic larynx 61.3 (45.5-71.1) 55.6 (26.2-70.4) 
Volume receiving ≥60 Gy (%)   
   EIM 3.3 (0-100) 3.3 (0-100) 
NTCP swallowing dysfunction (%)   
   RTOG Grade 2-4 42 (7-61) 33 (2-58) 
   Problems swallowing solid food 34 (11-66) 26 (3-62) 
   Problems swallowing soft food 16 (2-47) 13 (1-44) 
   Problems swallowing liquid food 7 (2-12) 6 (1-12) 
   Choking when swallowing 6 (1-37) 5 (0-36) 
Values are means with ranges in parenthesis. Abbreviations: cm=centimeter, EIM=esophageal inlet muscle, 
NTCP=normal tissue complication probability, PCM=pharyngeal constrictor muscle, PTVx=planning target vol-
ume prescribed x Gy, RTOG=Radiation Therapy Oncology Group, ST-IMRT=standard intensity modulated radio-
herapy, SW-IMRT=swallowing sparing intensity modulated radiotherapy, Vx=volume receiving ≥x Gy 
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Dose delivered to OARs and SWOARs 
All dose plans complied with the primary objectives for maximum allowed doses in the 
critical OARs and maximum allowed plan doses. The mean dose delivered to the parotid 
glands was similar for ST-IMRT and SW-IMRT (Table 2). The mean dose to the submandib-
ular glands was slightly higher with SW-IMRT. In general, sparing of the submandibular 
glands was minimal as on average 79% of the combined submandibular gland volume was 
inside the PTVs. The mean dose in the SWOARs was always lower with SW-IMRT. Absolute 
mean dose reductions in SWOARs with SW-IMRT relative to ST-IMRT were lowest for the 
middle PCM (4.2 Gy) and highest for the supraglottic larynx (5.6 Gy). In 29 patients the 
EIM V60 was zero with both ST-IMRT and SW-IMRT while in one patient it was 100% with 
either method. 
 
NTCP of swallowing dysfunction 
The NTCP values for swallowing dysfunction were lowest with SW-IMRT (Table 2). The 
mean NTCP reduction for physician-rated RTOG grade 2-4 swallowing dysfunction with 
SW-IMRT was 8.9% (range 3-20%). The mean NTCP reductions with SW-IMRT for patient-
rated moderate to severe swallowing problems were: 7.9% (range 3-16%) for solid food, 
2.4% (range 0-8%) for soft food, 1.4% (range 0-4%) for liquid food, and 0.9% (range 0-2%) 
for chocking when swallowing. 
 The absolute NTCP values for ST-IMRT and SW-IMRT, but also the absolute NTCP gain 
with SW-IMRT varied widely across individual patients (Figure 1). The results show that 
the NTCP values of physician-rated RTOG grade 2-4 swallowing dysfunction were lower in 
patients with laryngeal and hypopharyngeal tumors and in patients with N stages N0-N2b 
(Table 3). In addition, patients with oropharyngeal and nasopharyngeal tumors had higher 
NTCP values for problems with swallowing solid and soft foods and less from problems 
with swallowing liquids and choking when compared to patients with hypopharyngeal and 
laryngeal tumors. 
Discussion 
This paper is the first to report on reductions in swallowing dysfunction that may be ob-
tained in HNC patients by specific sparing of the SWOARs with SW-IMRT when compared 
to ‘standard’ parotid sparing IMRT. On average, the probability of physician-rated RTOG 
grade 2-4 swallowing dysfunction was reduced with SW-IMRT from 42% to 33%, with pa-
tient individual gains ranging from 3% to 20% when compared to ST-IMRT. In addition, 
patient-rated moderate to severe problems with swallowing solid, soft and liquid foods as 
well as the probability of choking when swallowing are expected to be lower with SW-
IMRT. These reductions were possible without compromising the dose to the PTV and the 
parotid glands, while the dose in other critical structures remained below accepted dose 
limits. 
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Figure 1. Normal Tissue Complication Probabilities (NTCP) of physician-rated Radiation Therapy Oncology 
Group (RTOG) grade 2-4 swallowing dysfunction (A), patient-rated moderate to severe problems with swal-
lowing solid food (B), soft food (C), liquid food (D), and choking when swallowing (E) with standard intensity 
modulated radiotherapy (ST-IMRT) and swallowing sparing IMRT (SW-IMRT) in 30 individual patients. The 
potential NTCP reduction with SW-IMRT compared with ST-IMRT and the corresponding proportion of pa-
tients who have at least the specified gain with respect to the different swallowing dysfunction related end-
points (F). Example, as depicted in the figure (F): 60% of the patients have at least 6% gain with SW-IMRT 
compared to ST-IMRT with respect to physician-rated RTOG grade 2-4 swallowing dysfunction, as well as with 
respect to patient-rated moderate to severe problems with swallowing solid food. 
 
 Others have previously investigated the effect of dose delivered to structures involved 
in swallowing or the potential dosimetric gains of SWOAR sparing with IMRT23–28. In most 
cases, the doses to the inferior SWOARs, such as the (supra)glottic larynx and the inferior 
PCM, were reduced by using split field (SF)-IMRT. SF-IMRT is often delivered with a 
matched anterior low neck field (LNF) with specific 2-3 cm wide blocking of the larynx. 
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Although this method has demonstrated to reduce the dose in the inferior SWOARs, a 
reduced coverage of the inferior part of the elective PTV had to be accepted. In the current 
study, we demonstrated that compromising PTV coverage is not necessary with SW-IMRT 
while sparing of the supraglottic larynx can be achieved, even with additional sparing of 
the superior and middle PCM. 
 In 2004, Eisbruch and colleagues already demonstrated the potential benefit of spar-
ing SWOARs with whole field IMRT23. Additional IMRT objectives for sparing the PCM and 
larynx could reduce the V50 of these structures with 10% and 7%, respectively, when com-
pared to regular IMRT with similar target coverage. Although in that study the dose in the 
PCM and larynx were related to abnormalities observed with video fluoroscopy, direct 
endoscopy and CT, the clinical relevance of the observed PCM and larynx V50 reductions 
could not be determined. It should also be noted that in that study, more IMRT segments 
were used in the SWOAR sparing plan and a 1.5 Gy increase of the parotid gland mean 
dose was accepted. In the current study, 84 segments were used with either technique 
and the parotid gland dose was not increased. In the study of Eisbruch et al.23, planning 
objectives were only set for the parts of the SWOARs that were located outside the PTVs. 
This may allow for a reduction of the V50, but this may also impair the reduction of the 
SWOAR mean dose, because it allows for a higher dose in the overlapping part of the 
SWOARs. For this reason, objectives to reduce the mean dose in the entire SWOARs were 
used in the current study. Altogether, very few data has been available until now demon-
strating the potential clinical relevance of SWOAR sparing in HCN relative to ‘standard’ 
parotid sparing IMRT. 
 In the current study, the objectives and corresponding SWOARs were based on the 
NTCP model parameters as developed in our institute. According to these NTCP models, 
the development of physician-rated RTOG grade 2-4 swallowing dysfunction was signifi-
cantly associated with the superior PCM and supraglottic larynx mean dose14. In our opti-
mization procedure, a maximal reduction of the superior PCM and supraglottic larynx 
mean dose had the highest priority, without violating the initial IMRT objectives. Reducing 
the mean dose in the middle PCM and the EIM V60 had lower priorities and the corre-
sponding objectives were entered after the superior PCM and supraglottic larynx mean 
dose were minimized. Although others have used specific dose constraints for OARs and 
SWOARs, below which no attempts were made to further decrease the dose25,29–33, in the 
current study it was attempted to reduce the mean dose in the parotid glands and 
SWOARs as much as possible, taking into account a specific order of priority based on 
different NTCP models. 
 The results of the current study show that the benefit of SW-IMRT differs widely 
across the individual patients. Furthermore, the initial probability of swallowing dysfunc-
tion with ST-IMRT differs across patients. This can be explained by the finding that both 
the initial NTCP of swallowing dysfunction and the possible NTCP reductions depend on 
pre-treatment factors such as age and tumor location and the initial dose to the SWOARs 
with ST-IMRT14. As presented in Table 3, we expect that patients with no or only ipsilateral 
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involved nodes (Nodal stage N0-N2b), will benefit more from SW-IMRT compared to pa-
tients with contralateral or bilateral nodal (N2C) metastasis. 
 It should be realized that during IMRT optimization, dose is often moved from one 
OAR to another and dose distributions that are highly conformal to the PTVs may also lead 
to an increased spill of low dose into normal tissues. In the current study, it appeared that 
the total V51.3 (95%*54 Gy) and the V57.8 (107%*54 Gy) were increased with SW-IMRT, 
i.e., the dose-to-target conformity of the plans had decreased. However, there is little 
knowledge with respect to the clinical relevant consequences of this increased spill of low 
dose into normal tissues. Because it was demonstrated that swallowing dysfunction has a 
major impact on the quality of life of HNC patients21, the increased V51.3 and V57.8 were 
accepted in the current study for the purpose of reducing the mean dose in the SWOARs. 
 Future research should be aimed at determining the order of priority of planning ob-
jectives, on the bases of specific patient characteristics. This may enable choosing the best 
optimization procedure and might therefore improve the benefit of SW-IMRT for individ-
ual patients. Furthermore, research should focus on the examination of new radiotherapy 
technology, such as scanned beam proton IMRT, to test the hypothesis that SWOAR spar-
ing can also be obtained without the need to increase the volumes receiving low and in-
termediate doses. However, a number of potential problems must be overcome first be-
fore HNC proton therapy can be implemented in clinical practice. It is a current research 
aim in our institute to test strategies which may improve HNC proton plan robustness. 
 In the current study, we only selected patients that received bilateral neck irradiation 
as sparing of SWOARs is most challenging in these patients. The current study population 
also included a higher percentage of patients with oropharyngeal tumors, with more ad-
vanced T-stages (T3 and T4 tumors) and more advanced N-stages compared to the cohort 
of our previous study (Table 1). Therefore, SWOAR sparing as well as parotid sparing was 
more difficult in the current population due to the generally larger target volumes and 
because most patients had a relatively large overlap between the target volumes, the pa-
rotid glands and the SWOARs. The actual gain of SW-IMRT in clinical practice might there-
fore differ from that in the current study. In order to validate our predictive models and 
to assess the actual benefits obtained with SW-IMRT, we recently started a prospective 
cohort study to evaluate if SW-IMRT will eventually result in the expected reductions of 
different endpoints related to swallowing. 
Conclusion 
The current in silico planning comparative study showed that sparing of SWOARs by using 
SW-IMRT has the potential to reduce the risk on swallowing problems after curative 
(chemo) radiotherapy. 
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